Background

Acute myeloid leukemia (AML) is a heterogeneous blood disease with poor treatment effect and high recurrence rate. With the deepening of non-coding RNA research, more and more miRNAs have been found to participate in various physiological processes of tumors. In this study, we tried to find the miRNA related to the prognosis of AML.

Methods

Collect gene expression data and clinical information of AML patients in the Cancer Genome Atlas database for statistical analysis. The expression level of miR-195 of each patient was standardized by logCPM and then produced as a box plot according to subtype classification. TargetScan was used to predict the target genes of miR-195, and these genes were subjected to GO pathway enrichment analysis by Metascape. Differential miRNAs were screened through the DESeq2 package in the R language. Survival rates were estimated using the Kaplan–Meier method and the log-rank test. The multivariate Cox proportional hazard models of EFS and OS were established.

Results

We found that the expression of miR-195 was the lowest in cytogenetically normal (CN-) AML, and high expression of miR-195 only promoted the prognosis of chemotherapy-only CN-AML patients (EFS: P = 0.016; OS: P = 0.035). Multivariate analysis showed that miR-195^high was a favorable and independent factor for CN-AML (both P < 0.05). Further analysis showed that miR-195 may affect signal transduction through ANHAK2 in AML.

Conclusion

We found that high expression of miR-195 can increase prognosis time of chemotherapy-only CN-AML patients, providing a new possibility for treatment.

中文翻译：

---

miR-195的高表达与细胞遗传学正常的急性髓细胞白血病的良好预后有关

背景

急性髓系白血病（AML）是一种异质性血液病，治疗效果差，复发率高。随着非编码RNA研究的深入，越来越多的miRNA被发现参与肿瘤的各种生理过程。在本研究中，我们试图寻找与 AML 预后相关的 miRNA。

方法

在 Cancer Genome Atlas 数据库中收集 AML 患者的基因表达数据和临床信息进行统计分析。将每位患者的 miR-195 表达水平通过 logCPM 标准化，然后根据亚型分类生成箱线图。TargetScan用于预测miR-195的靶基因，并通过Metascape对这些基因进行GO通路富集分析。通过 R 语言中的 DESeq2 包筛选差异 miRNA。使用 Kaplan-Meier 方法和对数秩检验估计存活率。建立了EFS和OS的多变量Cox比例风险模型。

结果

我们发现 miR-195 在细胞遗传学正常 (CN-) AML 中的表达最低，而 miR-195 的高表达仅促进仅接受化疗的 CN-AML 患者的预后（EFS：P  = 0.016；OS：P  = 0.035)。多因素分析显示，miR-195^高是 CN-AML 的有利和独立因素（均P  < 0.05）。进一步分析表明，miR-195 可能影响 AML 中通过 ANHAK2 的信号转导。

结论

我们发现miR-195的高表达可以延长单纯化疗的CN-AML患者的预后时间，为治疗提供了新的可能。